Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies “Arcus stands out as a mid-sized ...
PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig ...
SAN FRANCISCO & PHILADELPHIA--(BUSINESS WIRE)--W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced the ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rani Therapeutics Holdings (RANI – Research Report), Apollo Medical Holdings (AMEH – Research Report) and ...
Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies Arcus Biosciences, Inc. (NYSE:RCUS), a ...
Dr. Nuyten will oversee Arcus’s clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results